BenzingaAugust 31, 2026 at 9:45 AM NY4 days ago

B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story